Mustafa ALTINBAŞ

Tümörde Heterojen Yapı

___

1. Ding L, Ley TJ, Larson DE,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing. Nature 2012; 481(7382): 506-510.
2. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103:1139-1143.
3. Johnson BE, Mazor T, Hong C,et al. Mutational Analysis Reveals the Origin and Therapy-driven Evolution of Recurrent Glioma. Science 2014; 343(6167): 189-193.
4. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer?. Nature Reviews Cancer 2012; 12 (5): 323-334.
5. Lim JSJ, Lee SC. Understanding Intra-tumour Heterogeneity-- The Next Holy Grail of Cancer Therapeutics? Editorial. Annals Academy of Medicine 2014; 43(2): 72-73.
6. Marusyk A, Polyak K. Tumor heterogeneity: Causes and consequences. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2010; 1805 (1): 105-117.
7. Gerdes MJ, Sood A, Sevinksky C,et al. Emerging understanding of multiscale tumor heterogeneity. Front Oncol 2014; 4: 366.
8. Durrett R, Foo J, Leder K,et al. Heterogeneity in evolutionary models of tumor Progression. Genetics 2011; 188(2):461-477.
9. Büttner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Onco 2013; 31(15):1858-1865.
10. Gerlinger M, Rowan AJ, Horswell S,et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med 2012; 366 (10):883-892.